Abstract Type 2 diabetes (T2D) is a disease characterized by heterogeneously progressive
loss of islet β cell insulin secretion usually occurring after the presence of insulin resistance …

The global prevalence of obesity has more than doubled over the past four decades,
currently affecting more than a billion individuals. Beyond its recognition as a high-risk …

Background Obesity increases the risk of heart failure with preserved ejection fraction.
Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and …

Background Heart failure with mildly reduced or preserved ejection fraction (hereafter
referred to as HFpEF) is the most common type of heart failure and is associated with a high …

Background Semaglutide, a GLP-1 receptor agonist, reduces the risk of major adverse
cardiovascular events (MACE) in people with overweight or obesity, but the effects of this …

Background: Reports of reduced desire to smoke in patients treated with semaglutide, a
glucagon-like peptide receptor agonist (GLP-1RA) medication for type 2 diabetes mellitus …

For more than a century, physicians have searched for ways to pharmacologically reduce
excess body fat. The tide has finally turned with recent advances in biochemically …

Patients with obesity-related heart failure with preserved ejection fraction (HFpEF) display
circulatory volume expansion and pressure overload contributing to cardiovascular–kidney …

Background Obesity is associated with adverse cardiac remodeling and is a key driver for
the development and progression of heart failure (HF). Once-weekly semaglutide (2.4 mg) …

Abstract Background and Aims Evidence is lacking that correcting iron deficiency (ID) has
clinically important benefits for patients with heart failure with preserved ejection fraction …